RxDoctor Payments Data

Ashley Carter

Primary Care · Chicago, ILNPI 1073062154

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (53.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Edwards Lifesciences at 39.5% of the total. Reporting peaked in 2023 at $4,427 and has fallen 96.6% since, to $152 in 2025. Among primary care clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,100in general payments, 2019–2025

Across 84 payments — averaging $84.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$3K
  • Medtronic$3K
  • Boston Scientific$1K
  • Novartis$188
  • Abbott$168
  • Cardiva Medical, Inc.$120
  • plus $125 from 2 others

What the payments were for

  • Travel & lodging$3,80954%
  • Food & beverage$3,16145%
  • Education$1312%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Edwards Lifesciences35$2,807
Medtronic26$2,579
Boston Scientific8$1,114
Novartis9$188
Abbott2$168
Cardiva Medical, Inc.2$120
Novo Nordisk1$99
Pfizer1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,100 in reported general payments places this provider in the 95th percentile of 150 primary care providers in Illinois.

See all primary care providers in Illinois

Medicare billing

Part B allowed, 2024
$15,940
Medicare patients
145
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan14$10,771
EliquisApixaban11$7,671
Rosuvastatin Calcium34$402
Atorvastatin Calcium74$399
Prasugrel Hcl11$180
Carvedilol26$113
Metoprolol Succinate15$96
Amlodipine Besylate12$53
Furosemide19$30

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$188$10,77114 claims
PfizerEliquis$25$7,67111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 150 primary care providers in Illinois.

Other primary care in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →